A re-evaluation of the role of hctr1, the human high-affinity copper transporter, in platinum-drug entry into human cells

Molecular Pharmacology

Volumn 83, Issue 6, 2013, Pages 1237-1246

  Ivy, Kristin D ^a   Kaplan, Jack H ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CISPLATIN; COPPER; COPPER TRANSPORTER 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELLS; CONTROLLED STUDY; DRUG BINDING; DRUG PENETRATION; DRUG UPTAKE; EMBRYO; EMBRYO CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; KIDNEY CELL; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MICE;

EID: 84877815745     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.085068     Document Type: Article

References (52)

1. Ahmed Z, Deyama Y, Yoshimura Y, and Suzuki K (2009) Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na1,K1-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. Cancer Chemother Pharmacol 63:643-650.
2. Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 2:35-43. (Pubitemid 20218552)
3. Andrews PA, Velury S, Mann SC, and Howell SB (1988) cis- Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:68-73. (Pubitemid 18030332)
4. Ashino T, Sudhahar V, Urao N, Oshikawa J, Chen GF, Wang H, Huo Y, Finney L, Vogt S, and McKinney RD et al. (2010) Unexpected role of the copper transporter ATP7A in PDGF-induced vascular smooth muscle cell migration. Circ Res 107: 787-799.
5. Beretta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F, and Perego P (2004) Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and-resistant cells. Biochem Pharmacol 68:283-291. (Pubitemid 38757697)
6. Blumberger J, Bernasconi L, Tavernelli I, Vuilleumier R, and Sprik M (2004) Electronic structure and solvation of copper and silver ions: A theoretical picture of a model aqueous redox reaction. J Am Chem Soc 126:3928-3938. (Pubitemid 38391885)
7. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, and Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75:228-234.
8. Dancis A, Yuan DS, Haile D, Askwith C, Eide D, Moehle C, Kaplan J, and Klausner RD (1994) Molecular characterization of a copper transport protein in S. cerevisiae: An unexpected role for copper in iron transport. Cell 76:393-402.
9. De Feo CJ, Aller SG, and Unger VM (2007) A structural perspective on copper uptake in eukaryotes. Biometals 20:705-716. (Pubitemid 46776569)
10. Eisses JF and Kaplan JH (2002) Molecular characterization of hCTR1, the human copper uptake protein. J Biol Chem 277:29162-29171.
11. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, and Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396-402.
12. Fu S, Naing A, Fu C, Kuo MT, and Kurzrock R (2012) Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther 11:1221-1225.
13. Gale GR, Morris CR, Atkins LM, and Smith AB (1973) Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res 33:813-818.
14. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67:1171-1176. (Pubitemid 23172848)
15. Giaccone G. (2000) Clinical perspectives on platinum resistance. Drugs 59 (Suppl 4): 9-17; discussion 37-18. (Pubitemid 30344987)
16. Guo Y, Smith K, and Petris MJ (2004) Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: Requirement for the extracellular methioninerich clusters. J Biol Chem 279:46393-46399. (Pubitemid 39518280)
17. Hilder T and Hill J (2007) Modelling the encapsulation of the anticancer drug cisplatin into carbon nanotubes. Nanotechnology 18:275704.
18. Holzer AK and Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944-10952. (Pubitemid 44876993)
19. Holzer AK, Katano K, Klomp LW, and Howell SB (2004a) Cisplatin rapidly downregulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10:6744-6749. (Pubitemid 39346572)
20. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, and Howell SB (2004b) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66:817-823. (Pubitemid 39319453)
21. Ishida S, Lee J, Thiele DJ, and Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302. (Pubitemid 35257666)
22. Ishida S, McCormick F, Smith-McCune K, and Hanahan D (2010) Enhancing tumorspecific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17:574-583.
23. Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, and Howell SB (2009) Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15:553-560.
24. Kalayda GV, Wagner CH, and Jaehde U (2012) Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem 116:1-10.
25. Kaplan JH and Lutsenko S (2009) Copper transport in mammalian cells: Special care for a metal with special needs. J Biol Chem 284:25461-25465.
26. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, and Howell SB (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62:6559-6565. (Pubitemid 35364122)
27. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584. (Pubitemid 47106628)
28. Koepsell H and Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666-676. (Pubitemid 38241452)
29. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, and Sugiyama T et al. (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60:1312-1316. (Pubitemid 30152000)
30. Larson CA, Adams PL, Blair BG, Safaei R, and Howell SB (2010a) The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol Pharmacol 78:333-339.
31. Larson CA, Adams PL, Jandial DD, Blair BG, Safaei R, and Howell SB (2010b) The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochem Pharmacol 80:448-454.
32. Larson CA, Blair BG, Safaei R, and Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324-330.
33. Lee J, Petris MJ, and Thiele DJ (2002) Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem 277:40253-40259. (Pubitemid 35215596)
34. Liang ZD, Stockton D, Savaraj N, and Tien Kuo M (2009) Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol 76:843-853.
35. Lin X, Okuda T, Holzer A, and Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154-1159. (Pubitemid 35222507)
36. Loehrer PJ and Einhorn LH (1984) Drugs five years later. Cisplatin. Ann Intern Med 100:704-713.
37. Maryon EB, Molloy SA, and Kaplan JH (2007) O-linked glycosylation at threonine 27 protects the copper transporter hCTR1 from proteolytic cleavage in mammalian cells. J Biol Chem 282:20376-20387. (Pubitemid 47100022)
38. Molloy SA and Kaplan JH (2009) Copper-dependent recycling of hCTR1, the human high affinity copper transporter. J Biol Chem 284:29704-29713.
39. Narawa T, Tsuda Y, and Itoh T (2007) Chiral recognition of amethopterin enantiomers by the reduced folate carrier in Caco-2 cells. Drug Metab Pharmacokinet 22:33-40.
40. Pabla N, Murphy RF, Liu K, and Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296:F505-F511.
41. Palm ME, Weise CF, Lundin C, Wingsle G, Nygren Y, Björn E, Naredi P, Wolf-Watz M, and Wittung-Stafshede P (2011) Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro. Proc Natl Acad Sci USA 108:6951-6956.
42. Petris MJ, Smith K, Lee J, and Thiele DJ (2003) Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem 278:9639-9646. (Pubitemid 36800460)
43. Rabik CA and Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23. (Pubitemid 46137553)
44. Rabik CA, Maryon EB, Kasza K, Shafer JT, Bartnik CM, and Dolan ME (2009) Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 64:133-142.
45. Samimi G, Katano K, Holzer AK, Safaei R, and Howell SB (2004) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66:25-32. (Pubitemid 38822084)
46. Sinani D, Adle DJ, Kim H, and Lee J (2007) Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem 282:26775-26785. (Pubitemid 47501950)
47. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, and Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3: 1543-1549. (Pubitemid 40136709)
48. Tsai CY, Finley JC, Ali SS, Patel HH, and Howell SB (2012) Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochem Pharmacol 84:1007-1013.
49. Zimnicka AM, Ivy K, and Kaplan JH (2011) Acquisition of dietary copper: A role for anion transporters in intestinal apical copper uptake. Am J Physiol Cell Physiol 300:C588-C599.
50. Zimnicka AM, Maryon EB, and Kaplan JH (2007) Human copper transporter hCTR1 mediates basolateral uptake of copper into enterocytes: Implications for copper homeostasis. J Biol Chem 282:26471-26480. (Pubitemid 47443790)
51. Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, and Jaehde U (2007) Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 73:298-307. (Pubitemid 44855730)
52. Zumaeta E, Gonzalez Griego A, Ferrandiz J, Villanueva A, Soto V, Almeida R, Gonzalez VE, Gonzalez G, Lugo MG, and Ramirez V et al. (2001) Predicted duration of protective anti-HBs antigens in Peruvian health care workers after six years of vaccination. Rev Gastroenterol Peru 21:276-281. (in Spanish)b